Abstract：
Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify oncogenic drivers linked with better outcomes when treated upfront with targeted therapies. Mesenchymal-epithelial transition factor (MET) alterations are present in up to 60% of non-small cell lung cancer and are associated with a poor prognosis. Capmatinib and tepotinib are currently the only two approved targeted therapies by the U.S. Food and Drug Administration (FDA) for patients with MET exon 14 skipping mutation. Several agents are being developed to tackle an unmet need in patients with MET alterations. Some of these agents are being used in combination with EGFR targeted therapy to mitigate resistance to EGFR inhibitor. These agents are poised to provide new hope for these patients.
摘要：
精准医学已帮助确定了几种肿瘤分子畸变，以进行靶向治疗。这些疗法在具有晚期癌症的特定致癌驱动因素的患者中显示出功效的实质性改善而没有过度毒性。在转移性肺癌中，广泛的分子肿瘤测序平台的实施帮助肿瘤学提供者确定了在预先接受靶向治疗时与更好结局相关的致癌驱动因素.间充质-上皮转化因子（MET）改变存在于高达60％的非小细胞肺癌中，并与不良预后相关。Capmatinib和tepotinib是目前美国食品和药物管理局（FDA）批准的针对MET外显子14跳跃突变患者的两种靶向治疗方法。正在开发几种药物来解决MET改变患者的未满足需求。这些药物中的一些与EGFR靶向治疗组合使用以减轻对EGFR抑制剂的抗性。这些药物有望为这些患者提供新的希望。
